Home Overview Press Room Blog Publications For Students about us
Search

About the Biotech & Pharma Industries & Human Biotechnology


The fast-growing biotech industry is playing a dominant role in shaping the development, marketing and use of human biotechnologies. Like the pharmaceutical industry, it profits by developing products aimed at treating disease and restoring health. Although some biotech products and activities are socially and ethically controversial, the industry as a whole tends to oppose public oversight and regulation.

This situation is complicated by increasingly blurred lines between private biotechnology companies and university researchers, between perceptions of serving the public interest and the profit imperatives of private enterprise, and between research and commercialization.

In recent decades, the US Congress has enacted policies that allow controversial patents (such as those on gene sequences and human tissues), and that encourage closer university-corporate relations. These policies have led to a rapid commercialization of biology and medicine, and to a significant number of university-based researchers with financial ties to private companies. Such arrangements allow them to maintain the appearance of serving the public interest while pursuing careers in the private sector.

Private industry is an important player in the development of human biotechnologies. But the lack of a financially independent counterweight like the one that public universities used to provide makes effective oversight and responsible regulation imperative. Given the impact of the biotech industry on public debate, public policy, and all of our lives, its interests must be transparent.



The Lessons of Asilomar for Today’s Scienceby Alexander CapronThe New York TimesMay 28th, 2015Four decades ago, concerns about the science of recombinant DNA led to a global moratorium on cutting-edge research.
$15 Million for Calimmune and California Stem Cell HIV Trialby David JensenCalifornia Stem Cell ReportMay 27th, 2015Calimmune, Inc., which has received $8.3 million from the California stem cell agency, announced it has rustled up another $15 million to help out with the work that the agency is backing.
Study Reveals Shortcomings in Gene Testing; Results on Estimating Disease Risk Often Conflictby Marilynn MarchioneAssociated PressMay 27th, 2015The first report from a big public-private project to improve genetic testing reveals it is not as rock solid as many people believe.
Let’s Talk About the Ethics of Germline Modificationby Gregor WolbringImpact EthicsMay 27th, 2015We need clarity about where the public discussion should take place, what exactly it should focus on, and who should participate.
Center for Genetics and Society comments on White House and National Academies approaches to altering the human germline[Press statement]May 27th, 2015“The endorsement of a pause by the White House is an important first step."
The Scope of Eugenics: A Workshopby Jonathan ChernoguzMay 27th, 2015The four-day workshop, organized by the Edmonton-based Living Archives Project on Eugenics in Western Canada, brought together early-career scholars interested in eugenics to discuss historical models and forms of "Newgenics."
Here’s a Greek Business That’s Booming: Making Test-Tube Babiesby Maria PetrakisBloombergMay 25th, 2015“There might be a financial crisis, but people will still pay to get a child when they want one.”
So You’re Related to Charlemagne? You and Every Other Living European…by Adam RutherfordThe GuardianMay 24th, 2015The advent of cheap genetic sequencing has given birth to a burgeoning ancestry industry. But before you pay to spit in a tube, let me give you a few facts for free.
Public Polling on Human Genetic Modification: Mixed, but Favor Moratoriumby Paul KnoepflerKnoepfler Lab Stem Cell BlogMay 23rd, 2015The results make a case for more inclusion of the public in the dialogue on the use of gene editing in humans.
Why We Need To Talk Now About The Brave New World Of Editing Genesby Carey GoldbergWBURMay 22nd, 2015Suddenly, it’s no longer purely science fiction that humankind will have the ability to tinker with its own gene pool. But should it?
Displaying 1-10 of 1970  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760